Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C514S635000, C514S866000
Reexamination Certificate
active
06894058
ABSTRACT:
The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
REFERENCES:
patent: 5130333 (1992-07-01), Pan et al.
patent: 5190970 (1993-03-01), Pan et al.
patent: 5298497 (1994-03-01), Tschollar et al.
patent: 6103742 (2000-08-01), Ikeda et al.
patent: 6121295 (2000-09-01), Ikeda et al.
patent: 6169100 (2001-01-01), Ikeda et al.
patent: 6262076 (2001-07-01), Cameron et al.
patent: 6337327 (2002-01-01), Tuffin et al.
patent: 6384062 (2002-05-01), Ikeda et al.
patent: 6448280 (2002-09-01), Carey et al.
patent: 0 457 514 (1991-11-01), None
patent: 0 459 453 (1991-12-01), None
patent: 0 482 498 (1992-04-01), None
patent: 0 521 471 (1993-01-01), None
patent: 0 738 512 (1996-10-01), None
patent: WO 9513063 (1995-05-01), None
patent: WO 9526188 (1995-10-01), None
patent: WO 9737688 (1997-10-01), None
patent: WO 9911260 (1999-03-01), None
Budavari et al., The Merck Index, Twelfth Edition (1996), p. 1282, abstract No. 7605.*
Apfel, “Introduction to Diabetic Neuropathy”, Excerpta Medica, Inc., 1999, p. 1S.
Vinik, “Diabetic Neuropathy: Pathogenesis and Therapy”, Excerpta Medica, Inc., 1999, pp. 17S-26S.
Parry, “Management of Diabetic Neuropathy”, Excerpta Medica, Inc., 1999, pp. 27S-33S.
Simons et al., “Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia”, Atherosclorisis, vol. 137, 1998, pp. 197-203.
Watts et al., “Impaired endothelium-dependent and independent dilation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: roles of dyslipidaemia”, Clinical Science, vol. 91, 1996, pp. 567-573.
Mullen et al., “Atorvastatin But not L-Arginine Improves Endothelial Function in Type I Diabetes Mellitus: A Double-Blind Study”, Journal of American College of Cardiology, vol. 56, No. 2, Aug., 2000, pp. 410-416.
Sheu, Letter, Diabetes Care, Col. 22, No. 7, Jul. 1999, pp. 1224-1225.
Evans et al., “Ciprofibrate Therapy Improves Endothelial Function and Reduces Postprandial Lipernia and Oxidative Stress in Type 2 Diabetes Mellitus”, Circulation, Apr. 18, 2000, pp. 1773-1779.
Kamata et al., “Preservation of endothelium-dependent relaxation in cholesterol-fed and streptozotocin-induced diabetic mice by the chronic administration of cholestyramine”, British Journal of Pharmacology, vol. 118, 1996, pp. 385-391.
McClellan et al., “Candesartan Cilexetil A Review of its Use in Essential Hypertension”, Drugs, 1998, pp. 847-869.
Graham-Smith et al., “Oxford Handbook on Clinical Pharmacology and Pharmacology”, Moscow, “Meditsina” 2000, part 10 (Partial Translation).
Balabolkin, “Endicrinology”, Moscow, “Universum Publishing” 1998, pp 427-430 and 420-421 (Partial Translation).
Small Medical Encyclopedia, Moscow “Meditsina”, 199 pp. 110 (Partial Translation).
Cameron Norman E.
Cotter Mary A.
AstraZeneca AB
Weddington Kevin E.
LandOfFree
Use of 3-hydroxy-3-methylgutaryl coenzym a reductase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 3-hydroxy-3-methylgutaryl coenzym a reductase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 3-hydroxy-3-methylgutaryl coenzym a reductase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3370720